Cervical Cancer Screening Guidelines in the Postvaccination Era: Review of the Literature

Carlo A Liverani, Jacopo Di Giuseppe, Luca Giannella, Giovanni Delli Carpini, Andrea Ciavattini, Carlo A Liverani, Jacopo Di Giuseppe, Luca Giannella, Giovanni Delli Carpini, Andrea Ciavattini

Abstract

Cervical cancer is relatively rare in high-income countries, where organized screening programs are in place, as well as opportunistic ones. As the human papillomavirus (HPV) vaccination rates increase, the prevalence of cervical precancers and cancers is going to decrease rapidly very soon, even if, in the most optimistic scenario, it is unlikely that optimal vaccination coverage will be achieved. Then, the optimal screening paradigm for cervical cancer prevention in the postvaccination era is still debated. Screening guidelines are being developed with the aim of reducing the number of tests a woman needs during her lifetime, in order to receive the maximum benefit from screening, while decreasing potential harms that may result with the use of a screening strategy (overdiagnosis, overtreatment, anxiety, and costs). With this purpose in mind, new management guidelines for cervical cancer screening abnormalities are recommendations based on risks, not on results. This review aims to summarize the process that led to the introduction of the HPV DNA test in screening programs and the different screening strategies. Moreover, it aims to introduce the new risk-based guidelines for the future, where full HPV genotyping can resize the risk on the basis of specific high-risk genotypes. In the same way, the data regarding HPV vaccination could be introduced as soon as women vaccinated with the nonavalent vaccine reach the screening age, with the recommendation of a prolonged screening interval.

Conflict of interest statement

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Copyright © 2020 Carlo A. Liverani et al.

References

    1. WHO regional office for Europe, available on .
    1. Ronco G., Dillner J., Elfström K. M., et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. The Lancet. 2014;383(9916):524–532. doi: 10.1016/S0140-6736(13)62218-7.
    1. Wright T. C., Stoler M. H., Behrens C. M., Sharma A., Zhang G., Wright T. L. Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. Gynecologic Oncology. 2015;136(2):189–197. doi: 10.1016/j.ygyno.2014.11.076.
    1. Lew J.-B., Simms K. T., Smith M. A., et al. Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the national cervical screening program. The Lancet. Public Health. 2017;2(2):e96–e107. doi: 10.1016/S2468-2667(17)30007-5.
    1. Tota J. E., Bentley J., Blake J., et al. Introduction of molecular HPV testing as the primary technology in cervical cancer screening: acting on evidence to change the current paradigm. Preventive Medicine. 2017;98:5–14. doi: 10.1016/j.ypmed.2016.11.029.
    1. von Karsa L., Arbyn A., De Vuyst H., et al. Executive summary. In: Anttila A., Arbyn A., De Vuyst H., et al., editors. European Guidelines for Quality Assurance in Cervical Cancer Screening. Second. Luxembourg: Office for Official Publications of the European Union; 2015.
    1. Saslow D., Solomon D., Lawson H. W., et al. American cancer society, American society for colposcopy and cervical pathology, and American society for clinical pathology screening guidelines for the prevention and early detection of cervical cancer. CA: A Cancer Journal for Clinicians. 2012;62(3):147–172. doi: 10.3322/caac.21139.
    1. Massad L. S., Einstein M. H., Huh W. K., et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstetrics & Gynecology. 2013;121(4):829–846. doi: 10.1097/AOG.0b013e3182883a34.
    1. Moyer V. A., U.S. Preventive Services Task Force Screening for cervical cancer: U.S. preventive services task force recommendation statement. Annals of Internal Medicine. 2012;156(12):880–891. doi: 10.7326/0003-4819-156-12-201206190-00424.
    1. Fontham E. T. H., Wolf A. M. D., Church T. R., et al. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American cancer society. CA: A Cancer Journal for Clinicians. 2020;70(5):p. 321. doi: 10.3322/caac.21628.
    1. US Preventive Services Task Force, Guerra S. J., Curry S. J., Krist A. H, et al. Screening for cervical cancer: U S preventive services task force recommendation statement. JAMA. 2018;320(7):674–686. doi: 10.1001/jama.2018.10897.
    1. Winer R. L., Feng Q., Hughes J. P., O’Reilly S., Kiviat N. B., Koutsky L. A. Risk of female human papillomavirus acquisition associated with first male sex partner. The Journal of Infectious Diseases. 2008;197(2):279–282. doi: 10.1086/524875.
    1. Holowaty P., Miller A. B., Rohan T., To T. Natural history of dysplasia of the uterine cervix. JNCI Journal of the National Cancer Institute. 1999;91(3):252–258. doi: 10.1093/jnci/91.3.252.
    1. Liverani C. A. The four steps in the prevention of human papillomavirus-associated neoplasia. Archives of Gynecology and Obstetrics. 2013;288(5):979–988. doi: 10.1007/s00404-013-3011-9.
    1. Liverani C. A., Vercellini P., Frattaruolo M. P., Bolis G. What is and what should never be: use and misuse of HPV testing in cervical cancer prevention strategies. Current Women s Health Reviews. 2014;10(2):113–119. doi: 10.2174/157340481002150303154443.
    1. Solomon D., Papillo J. L., Davey D. D., Cytopathology Education and Technology Consortium Statement on HPV DNA test utilization. Journal of Lower Genital Tract Disease. 2009;131(6):768–769. doi: 10.1309/AJCPQCIBCZ22ZIMG.
    1. Davey D. D., Goulart R., Nayar R., Cytopathology Education and Technology Consortium (CETC) Statement on human papillomavirus DNA test utilization. American Journal of Clinical Pathology. 2014;141(4):459–461. doi: 10.1309/AJCPKXBQLWOJ4ZUB.
    1. Kyrgiou M., Athanasiou A., Kalliala I. E. J, et al. Obstetric outcomes after conservative treatment for cervical intraepithelial lesions and early invasive disease. The Cochrane Database of Systematic Reviews. 2017;11(11) doi: 10.1002/14651858.CD012847Castle.CD012847
    1. Castle P. E. Screening: HPV testing for cervical cancer: the good, the bad, and the ugly. Nature Reviews Clinical Oncology. 2010;7(7):364–365. doi: 10.1038/nrclinonc.2010.96.
    1. Flanagan M. B. Primary high-risk human papillomavirus testing for cervical cancer screening in the United States: is it time? Archives of Pathology & Laboratory Medicine. 2018;142(6):688–692. doi: 10.5858/arpa.2018-0001-ra.
    1. Musselwhite L. W., Oliveira C. M., Kwaramba T., et al. Racial/ethnic disparities in cervical cancer screening and outcomes. Acta Cytologica. 2016;60(6):518–526. doi: 10.1159/000452240.
    1. Rossi P. G., Baldacchini F., Ronco G. The possible effects on socio-economic inequalities of introducing HPV testing as primary test in cervical cancer screening programs. Frontiers in Oncology. 2014;4(20) doi: 10.3389/fonc.2014.00020.
    1. Saslow D., Castle P. E., Cox J. T., et al. American cancer society guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA: A Cancer Journal for Clinicians. 2007;57(1):7–28. doi: 10.3322/canjclin.57.1.7.
    1. Leeson S. C., Alibegashvili T., Arbyn M., et al. HPV testing and vaccination in Europe. Journal of Lower Genital Tract Disease. 2014;18(1):61–69. doi: 10.1097/LGT.0b013e318286b8d3.
    1. Nanda K., McCrory D. C., Myers E. R., et al. Accuracy of the papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Annals of Internal Medicine. 2000;132(10):810–819. doi: 10.7326/0003-4819-132-10-200005160-00009.
    1. Hegde D., Shetty P., Shetty H., Rai S. Diagnostic value of acetic acid comparing with conventional pap smear in the detection of colposcopic biopsy-proved CIN. Journal of Cancer Research and Therapeutics. 2011;7(4):454–458. doi: 10.4103/0973-1482.92019.
    1. Yoshida Y., Sato S., Okamura C., Nishino Y., Yajima A. Evaluating the accuracy of uterine cancer screening with the regional cancer registration system. Acta Cytologica. 2001;45(2):157–162. doi: 10.1159/000327270.
    1. Koliopoulos G., Nyaga V. N., Santesso N., et al. Cytology versus HPV testing for cervical cancer screening in the general population. The Cochrane Database of Systematic Reviews. 2017;8(8) doi: 10.1002/14651858.CD008587.pub2.CD008587
    1. Arbyn M., de Sanjosé S., Saraiya M., et al. EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease. International Journal of Cancer. 2012;131(9):1969–1982. doi: 10.1002/ijc.27650.
    1. Kotaniemi-Talonen L., Anttila A., Malila N., et al. Screening with a primary human papillomavirus test does not increase detection of cervical cancer and intraepithelial neoplasia 3. European Journal of Cancer. 2008;44(4):565–571. doi: 10.1016/j.ejca.2007.12.002.
    1. Leinonen M. K., Nieminen P., Lönnberg S., et al. Detection rates of precancerous and cancerous cervical lesions within one screening round of primary human papillomavirus DNA testing: prospective randomised trial in Finland. BMJ. 2012;345:p. e7789. doi: 10.1136/bmj.e7789.
    1. Bulkmans N., Berkhof J., Rozendaal L., et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. The Lancet. 2007;370(9601):1764–1772. doi: 10.1016/s0140-6736(07)61450-0.
    1. Ronco G., Segnan N., Giorgi-Rossi P., et al. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. Journal of the National Cancer Institute. 2006;98(11):765–774. doi: 10.1093/jnci/djj209.
    1. Ronco G., Giorgi-Rossi P., Carozzi F., et al. Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. The Lancet Oncology. 2006;7(7):547–555. doi: 10.1016/s1470-2045(06)70731-8.
    1. Naucler P., Ryd W., Törnberg S., et al. Human papillomavirus and papanicolaou tests to screen for cervical cancer. New England Journal of Medicine. 2007;357(16):1589–1597. doi: 10.1056/nejmoa073204.
    1. Kitchener H. C., Almonte M., Thomson C., et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. The Lancet Oncology. 2009;10(7):672–682. doi: 10.1016/s1470-2045(09)70156-1.
    1. Massad L. S. Assessing new technologies for cervical cancer screening: beyond sensitivity. Journal of Lower Genital Tract Disease. 2008;12(4):311–315. doi: 10.1097/lgt.0b013e31817d750c.
    1. McCredie M. R., Sharples K. J., Paul C., et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. The Lancet Oncology. 2008;9(5):425–434. doi: 10.1016/s1470-2045(08)70103-7.
    1. Barken S. S., Rebolj M., Andersen E. S., Lynge E. Frequency of cervical intraepithelial neoplasia treatment in a well-screened population. International Journal of Cancer. 2012;130(10):2438–2444. doi: 10.1002/ijc.26248.
    1. Lee J. W.-Y., Berkowitz Z., Saraiya M. Low-risk human papillomavirus testing and other nonrecommended human papillomavirus testing practices among U.S. health care providers. Obstetrics & Gynecology. 2011;118(1):4–13. doi: 10.1097/aog.0b013e3182210034.
    1. Castle P. E. Abuses in human papillomavirus DNA testing. Obstetrics & Gynecology. 2011;118(1):1–3. doi: 10.1097/aog.0b013e3182228630.
    1. Booth C. N., Bashleben C., Filomena C. A., et al. Monitoring and ordering practices for human papillomavirus in cervical cytology: findings from the college of American Ppathologists gynecologic cytopathology quality consensus conference working group 5. Archives of Pathology & Laboratory Medicine. 2013;137(2):214–219. doi: 10.5858/arpa.2012-0114-cp.
    1. WHO Publication: HPV tests for cervical cancer screening available on .
    1. HPV tests validated for screening. italian group for screening of cervical cancer GISCI (March 2020). Available on .
    1. Hopenhayn C., Christian A., Christian W. J., et al. Prevalence of human papillomavirus types in invasive cervical cancers from 7 US cancer registries before vaccine introduction. Journal of Lower Genital Tract Disease. 2014;18(2):182–189. doi: 10.1097/lgt.0b013e3182a577c7.
    1. Giannella L., Delli Carpini G., Di Giuseppe J., Prandi S., Tsiroglou D., Ciavattini A. Age-related changes in the fraction of cervical intraepithelial neoplasia grade 3 related to HPV genotypes included in the nonavalent vaccine. Journal of Oncology. 2019;2019 doi: 10.1155/2019/7137891.7137891
    1. Blatt A. J., Kennedy R., Luff R. D., Austin R. M., Rabin D. S. Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices. Cancer Cytopathology. 2015;123(5):282–288. doi: 10.1002/cncy.21544.
    1. McCarthy E., Ye C., Smith M., Kurtycz D. F. I. Molecular testing and cervical screening: will one test fit all? Journal of the American Society of Cytopathology. 2016;5(6):331–338. doi: 10.1016/j.jasc.2016.08.001.
    1. Pirog E. C., Lloveras B., Lloveras B., et al. HPV prevalence and genotypes in different histological subtypes of cervical adenocarcinoma, a worldwide analysis of 760 cases. Modern Pathology. 2014;27(12):1559–1567. doi: 10.1038/modpathol.2014.55.
    1. Austin R. M. Can HPV primary screening reduce cervical cancer incidence and mortality? SCAN. 2014;25(1):7–8.
    1. Zhou X., Sun L., Yao X., Li G., Wang Y., Lin Y. Progress in vaccination of prophylactic human papillomavirus vaccine. Front Immunol. 2020;11:p. 1434. doi: 10.3389/fimmu.2020.01434.
    1. WHO GLOBOCAN report 2018. Available on: .
    1. European parliamentary forum for sexual and reproductive rights. January 2020. Available on .
    1. IARC 2005, Cervix cancer screening, available on .
    1. Chrysostomou A., Stylianou D., Constantinidou A., Kostrikis L. Cervical cancer screening programs in Europe: the transition towards HPV vaccination and population-based HPV testing. Viruses. 2018;10(12):p. 729. doi: 10.3390/v10120729.
    1. Arbyn M., Anttila A., Jordan J., et al. European guidelines for quality assurance in cervical cancer screening. second edition-summary document. Annals of Oncology. 2010;21(3):448–458. doi: 10.1093/annonc/mdp471.
    1. Arbyn M., Gultekin M., Morice P., et al. The European response to the WHO call to eliminate cervical cancer as a public health problem. International Journal of Cancer. 2020 doi: 10.1002/ijc.33189.
    1. Arbyn M., Rebolj M., De Kok I. M. C. M., et al. The challenges of organising cervical screening programmes in the 15 old member states of the European union. European Journal of Cancer. 2009;45(15):2671–2678. doi: 10.1016/j.ejca.2009.07.016.
    1. Italian Health System data, .
    1. Vink M. A., Bogaards J. A., Meijer C. J. L. M., Berkhof J. Primary human papillomavirus DNA screening for cervical cancer prevention: can the screening interval be safely extended? International Journal of Cancer. 2015;137(2):420–427. doi: 10.1002/ijc.29381.
    1. OECD Health Data 2012 Database. National Health Service . London, UK: NHS Cervical Screening Programme; 2011. .
    1. Public Health England. Colposcopy and Programme Management. Third. London, UK: Public Health England; 2016. NHS cervical screening programme.
    1. Bogaards Z., Panayotova Y., Amati C., Baili P. On behalf of the EUROCHIP working group. Cancer Epidemiology. 2011;35(2):160–164.
    1. Cox J. T., Castle P. E., Behrens C. M., et al. Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16/18: results from the ATHENA HPV study. American Journal of Obstetrics and Gynecology. 2013;208:184.e1–184.e11. doi: 10.1016/j.ajog.2012.11.020.
    1. Jackson B. Overtesting for cervical cancer: patterns and trends from a national reference laboratory in the United States. Proceedings of the 2014 Preventing Overdiagnosis Conference; September 2014; Oxford, UK;
    1. Huh W. K., Ault K. A., Chelmow D., et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Gynecologic Oncology. 2015;136(2):178–182. doi: 10.1016/j.ygyno.2014.12.022.
    1. Zhou H., Mody R., Luna E., et al. The sensitivity of the cobas HPV Test in detecting biopsy-confirmed CIN2/3 cervical lesions: analysis of 33,857 cases with cytology and HPV co-testing. Journal of the American Society of Cytopathology. 2014;3(5):p. S3. doi: 10.1016/j.jasc.2014.09.007.
    1. Workowski K. A., Bolan G. A., Centers for Disease Control and Prevention—Atlanta Sexually transmitted diseases treatment guidelines 2015. MMWR Recommendations and Reports. 2015;64(RR-03):1–137.
    1. Perkins R. B., Guido R. S., Castle P. E., et al. 2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors. Journal of Lower Genital Tract Disease. 2020;24(2):102–131. doi: 10.1097/LGT.0000000000000525.
    1. Canadian Task Force on Preventive Health Care. Recommendations on screening for cervical cancer. CMAJ. 2013;185(1):35–45.
    1. OECD health data 2012 database, .
    1. Murillo R., Almonte M., Pereira A., et al. Cervical cancer screening programs in Latin America and the Caribbean. Vaccine. 2008;26(Suppl 11):L37–L48. doi: 10.1016/j.vaccine.2008.06.013.
    1. Villa L. L. Cervical cancer in Latin America and the Caribbean: the problem and the way to solutions. Cancer Epidemiology Biomarkers & Prevention. 2012;21(9):1409–1413. doi: 10.1158/1055-9965.epi-12-0147.
    1. Hammond I., Saville M. National Cervical Screening Program: Guidelines for the Management of Screen-Detected Abnormalities, Screening in Specific Populations and Investigation of Abnormal Vaginal Bleeding . Sydney, Australia: Cancer Council Australia; 2020. Cancer council Australia cervical cancer screening guidelines working party. .
    1. Hamashima C., Aoki D., Miyagi E., et al. The Japanese guideline for cervical cancer screening. Japanese Journal of Clinical Oncology. 2010;40(6):485–502. doi: 10.1093/jjco/hyq036.
    1. Kobayashi D., Takahashi O., Hikosaka C., Okubo T., Fukui T. Optimal cervical cytology mass screening interval for cervical cancer. Archives of Gynecology and Obstetrics. 2013;287(3):549–554. doi: 10.1007/s00404-012-2588-8.
    1. Palcic C. Cervical screening in China: project management considerations. International Cost Engineering Council (ICEC) 2011 , 2011, Available on .
    1. Black E., Richmond R. Prevention of cervical cancer in sub-saharan Africa: the advantages and challenges of HPV vaccination. Vaccines. 2018;6(3):p. 61. doi: 10.3390/vaccines6030061.
    1. Msyamboza K. P., Phiri T., Sichali W., Kwenda W., Kachale F. Cervical cancer screening uptake and challenges in Malawi from 2011 to 2015: retrospective cohort study. BMC Public Health. 2016;16(1):p. 806. doi: 10.1186/s12889-016-3530-y.
    1. Beddoe A. M. Elimination of cervical cancer: challenges for developing countries. Ecancermedicalscience. 2019;13:p. 975. doi: 10.3332/ecancer.2019.975.
    1. Cousins S. 2019. How Rwanda could be the first country to wipe out cervical cancer Mosaic [ ] Date accessed: 06/10/2020.
    1. Sancho-Garnier H., Khazraji Y. C., Cherif M. H., et al. Overview of cervical cancer screening practices in the extended Middle East and North Africa countries. Vaccine. 2013;31(Suppl 6):G51–G57. doi: 10.1016/j.vaccine.2012.06.046.
    1. Osgul R., Mbele M., Makhafola T., et al. Cervical cancer in low and middle‑income countries (Review) Oncology Letters. 2020;20(3):2058–2074. doi: 10.3892/ol.2020.11754.
    1. Mehrotra N., Naidoo M., Moodley I. Human papillomavirus (HPV) vaccination of adolescents in the South African private health sector: lessons from the HPV demonstration project in KwaZulu-Natal. South African Medical Journal. 2015;105(11):p. 954. doi: 10.7196/samj.2015.v105i11.10135.
    1. Jayant K., Sankaranarayanan R., Thorat R. V., et al. Improved survival of cervical cancer patients in a screened population in rural India. Asian Pacific Journal of Cancer Prevention: APJCP. 2016;17(11):4837–4844. doi: 10.22034/APJCP.2016.17.11.4837.
    1. Ali S., Skirton H., Clark M. T., Donaldson C. Integrative review of cervical cancer screening in western asian and middle eastern Arab countries. Nursing & Health Sciences. 2017;19(4):414–426. doi: 10.1111/nhs.12374.
    1. Cheung L. C., Egemen D., Chen X., et al. 2019 ASCCP risk-based management consensus guidelines: methods for risk estimation, recommended management, and validation. Journal of Lower Genital Tract Disease. 2020;24(2):90–101. doi: 10.1097/LGT.0000000000000528.
    1. Egemen D., Cheung L. C., Chen X., et al. Risk estimates supporting the 2019 ASCCP risk-based management consensus guidelines. Journal of Lower Genital Tract Disease. 2020;24(2):132–143. doi: 10.1097/LGT.0000000000000529.
    1. Perkins R. B., Fuzzell L. N., Lake P., et al. Incorporating stakeholder feedback in guidelines development for the management of abnormal cervical cancer screening tests. Journal of Lower Genital Tract Disease. 2020;24(2):167–177. doi: 10.1097/LGT.0000000000000524.
    1. Bonde J. H., Sandri M.-T., Gary D. S., Andrews J. C. Clinical utility of human papillomavirus genotyping in cervical cancer screening: a systematic review. Journal of Lower Genital Tract Disease. 2020;24(1):1–13. doi: 10.1097/LGT.0000000000000494.
    1. Farag S., Fields J., Pereira E., Chyjek K., Chen K. T. Identification and rating of gynecologic oncology applications using the applications scoring system. Telemedicine and e-Health. 2016;22(12):1001–1007. doi: 10.1089/tmj.2016.0040.
    1. Moodley J., Constant D., Botha M. H., van der Merwe F. H., Edwards A., Momberg M. Exploring the feasibility of using mobile phones to improve the management of clients with cervical cancer precursor lesions. BMC Women’s Health. 2019;19(1) doi: 10.1186/s12905-018-0702-1.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe